463-72-9

Usage

Uses

Carbamoyl chloride can be used as an intermediate for carbamate pesticides.

Synthesis

Carbamoyl chloride can be synthesized from methylamine and phosgene at 200-240℃.

Upstream product

• 75-44-5 phosgene 
• 108-80-5 isocyanuric acid 
• 590-28-3 potassium cyanate 
• 7647-01-0 hydrogenchloride 
• 108-20-3 di-isopropyl ether 
• 109-60-4 1-Propyl acetate 
• 108-91-8 cyclohexylamine 
• 89938-22-7 6-chloro-1,2,3,4-tetrahydroquinoxalin-2-one 
• 99938-53-1 N-(n-propyl)ethanolamine 3,5,6-trichloropyridylether 
• 2328-12-3 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline monohydrochloride 
• 96-31-1 N,N'-Dimethylurea 
• 108-80-5 cyanuric acid 
• 7664-41-7 ammonia 
• 43172-95-8 N-propyl-N-(2-chloroallyl)carbamoyl chloride 

Downstream Products

• 627-30-5 1-chloro-3-hydroxypropane 
• 5813-89-8 2-thiophenylcarboxamide 
• 22353-82-8 5-chlorothiophene-2-carboxamide 
• 98547-25-2 3,5-dimethyl-thiophene-2-carboxylic acid amide 
• 598-55-0 methyl carbamate 
• 630112-53-7 1-carbamoyl-3-methylhydantoin 
• 4551-72-8 pyrrole-2-carboxamide 
• 643087-31-4 2-methoxy-5-methylbenzamide 
• 23806-24-8 3-methyl-2-thiophenecarboxylic acid 
• 76655-99-7 3-Methyl-2-thiophenecarboxamide 
• 590-60-3 carbamic acid tert-pentyl ester 
• 1521-41-1 veratramide 
• 92049-93-9 carbamate de 2,6-dimethoxyphenyle 
• 5438-19-7 4-propoxybenzoic acid 

Relevant academic research and scientific papers

Azepinoindole derivatives as pharmaceutical agents

Compounds, compositions and methods for modulating the activity of receptors are provided. In particular, compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

Novel imidazotriazinones and the use thereof

Novel imidazotrizinones of general formula (I), a method for the production and the pharmaceutical use thereof are disclosed.

Use of hexahydrolupulones as antibacterial agents

Provided are functionalized silicon compounds and methods for their synthesis and use. The functionalized silicon compounds include at least one activated silicon group and at least one derivatizable functional group. Exemplary derivatizable functional groups include hydroxyl, amino, carboxyl and thiol, as well as modified forms thereof, such as activated or protected forms. The functionalized silicon compounds may be covalently attached to surfaces to form functionalized surfaces which may be used in a wide range of different applications. In one embodiment, the silicon compounds are attached to the surface of a substrate comprising silica, such as a glass substrate, to provide a functionalized surface on the substrate, to which molecules, including polypeptides and nucleic acids, may be attached. In one embodiment, after covalent attachment of a functionalized silicon compound to the surface of a solid silica substrate to form a functionalized coating on the substrate, an array of nucleic acids may be covalently attached to the substrate. Thus, the method permits the formation of high density arrays of nucleic acids immobilized on a substrate, which may be used, for example, in conducting high volume nucleic acid hybridization assays.

Method for making aliphatic diisocyanates

A method for making an aliphatic diisocyanate by (a) phosgenating an aliphatic diamine in the presence of an inert solvent or gas to form a crude reaction mixture; (b) distilling the crude reaction mixture to form an aliphatic diisocyanate production stream and an aliphatic diisocyanate waste stream; (c) introducing the aliphatic diisocyanate waste stream to a chamber and placing the waste stream under supercritical fluid conditions sufficient to dissolve an appreciable amount of the aliphatic diisocyanate component in the supercritical fluid; (d) separating the dissolved aliphatic diisocyanate component from the waste stream, wherein the remaining waste stream is a supercritically-purged aliphatic diisocyanate waste stream; (e) lowering the pressure sufficiently to precipitate the aliphatic diisocyanate component.

Preparation of high dye-yield couplers and intermediates useful therein

Disclosed is a carbamyl chloride of an aminoarylcarbonyl compound having the structural formula I: whereinR is an alkyl, alkenyl, or aryl group;A is an aryl (including heteroaryl) ring group;each R′ is independently an alkyl group which may form a ring with Z or Z′;p is 0, 1, 2, or 3;each Z, Z′, and Y is independently hydrogen or a substituent; andn is 0, 1, or 2.

Functionalized silicon compounds and methods for their synthesis and use

Provided are functionalized silicon compounds and methods for their synthesis and use. The functionalized silicon compounds include at least one activated silicon group and at least one derivatizable functional group. Exemplary derivatizable functional groups include hydroxyl, amino, carboxyl and thiol, as well as modified forms thereof, such as activated or protected forms. The functionalized silicon compounds may be covalently attached to surfaces to form functionalized surfaces which may be used in a wide range of different applications. In one embodiment, the silicon compounds are attached to the surface of a substrate comprising silica, such as a glass substrate, to provide a functionalized surface on the substrate, to which molecules, including polypeptides and nucleic acids, may be attached. In one embodiment, after covalent attachment of a functionalized silicon compound to the surface of a solid silica substrate to form a functionalized coating on the substrate, an array of nucleic acids may be covalently attached to the substrate. Thus, the method permits the formation of high density arrays of nucleic acids immobilized on a substrate, which may be used, for example, in conducting high volume nucleic acid hybridization assays.

Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines

Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.

Processes for making and using alkylaminoarylcarbonyl compounds

A method of making an alkylaminoarylcarbonyl compound having Formula I: wherein R is an alkyl group; A is an aryl (including heteroaryl) ring; each R' is independently an alkyl group which may form a ring with Z or Z'; p is 0, 1, 2, or 3; each Z, Z', and Y is independently hydrogen or a substituent; and n is 0, 1, or 2; comprising: (a) blocking the carbonyl function of an aminoarylcarbonyl compound via condensation with an active methylene compound (b) alkylating this blocked amniocarbonyl compound via reductive alkylation with an alkyl or aryl (including heteroaryl) carbonyl compound, and (c) deblocking of the blocked alkylaminoarylcarbonyl compound via base hydrolysis to regenerate the carbonyl function and give the desired alkylaminocarbonyl compound.

TRICYCLIC SUBSTITUTED HEXAHYDROBENZ [E]ISOINDOLE ALPHA-1 ADRENERGIC ANTAGONISTS

The present invention relates to a compound of the formula STR1 and the pharmaceutically acceptable salts thereof wherein W is a tricyclic heterocyclic ring system; which is an α-1 adrenergic antagonist and is useful in the treatment of BPH; also disclosed are . alpha.-1 antagonist compositions and a method for antagonizing α-1 receptors and treating BPH.

Imidazo[1,5-A]quinoxalines

An invention relating to Imidazo[1,5-a]quinoxalines (I) STR1 which do not contain an endocyclic carbonyl group and which are useful as anxiolytic and sedative/hypnotic agents.